BDTX 주가 차트
BDTX 재무
Black Diamond Therapeutics Inc
$1.95
1.56%
$0.03
종가: Aug 07, 16:00:00 GMT-4
$1.93
-1.02%
$-0.02
애프터마켓: Aug 07, 20:00:00 GMT-4
뒤로
Black Diamond Therapeutics Inc (BDTX) 재무
주요 통계
이전 종가
$1.92
시가
$1.95
일일 범위
$1.9 - $1.98
52주 범위
$1.6 - $4.94
거래량
598.0K
평균 거래량
1.4M
배당수익률
--
EPS(TTM)
-0.76
시가총액
$110.5M
BDTX란 무엇인가요?
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
